Results 311 to 320 of about 8,790,513 (336)

[Non-parametric methods for estimating confidence intervals around the incremental cost-effectiveness ratio].

Epidemiologia e prevenzione, 2008
In recent years, cost-effectiveness analysis has become a frequent component of randomized clinical trials. In statistical terms, the major efforts addressed the method for estimating the Incremental Cost Effectiveness Ratio (ICER) and its confidence interval both with parametric and non-parametric methods.
PETRINCO M, GREGORI, DARIO, LAZZARATO F, BRUNELLO F, VELTRI A, BERCHIALLA P, PAGANO E.   +6 more
openaire   +2 more sources

Comparing Manufacturer Submitted and Pan-Canadian Oncology Drug Review Reanalysed Incremental Cost-Effectiveness Ratios for Novel Oncology Drugs

Current Oncology, 2021
Kelvin K W Chan, Ronak Saluja, Matthew C Cheung   +2 more
exaly  

4CPS-029 Pembrolizumab, nivolumab and atezolizumab: incremental cost-effectiveness ratio

Section 7: Post Congress additions, 2022
R Tamayo Bermejo, JC Del Río Valencia, B Mora Rodríguez, I Muñoz Castillo   +3 more
openaire   +1 more source

Incremental Cost-Effectiveness Ratio (ICER)

2013
Marie Boltz, Holly Rau, Paula Williams, Holly Rau, Paula Williams, Jane Upton, Jos A. Bosch, Victoria E. Burns, Jos A. Bosch, Leila Anane, Jos A. Bosch, Joanna Long, Barbara Mullan, Peter M. Gollwitzer, Gabriele Oettingen, Kelly Winter, Jason S. Yeh, Susannah D. Copland, Douglas Carroll, Austin S. Baldwin, Valerie G. Loehr, Linda C. Baumann, Alyssa Karel, Mark T. Drayson, Anna C. Phillips, Pamela A. Geller, Alexandra Nelson, Nicolas Rohleder, Jutta M. Wolf, Yukari Tanaka, Shin Fukudo, Yoshiyuki Takimoto, J. Rick Turner, Laura Rodriguez-Murillo, Rany M. Salem, Wendy Troxel, Martica H. Hall, Elizabeth Galik, Yoshiyuki Takimoto, Adriana Carrillo, Della Matheson, Alan M. Delamater, Janine Sanchez, Luigi Meneghini, Margaret A. Chesney, David E. Anderson, Peter A. Hall, Nicolas Rohleder, Neil Schneiderman, Ulf-Dietrich Reips, Timothy W. Smith, Bert N. Uchino, Kimberly Bowen, McKenzie Carlisle, Maija Reblin, Rebecca Campo, Nelli Hankonen, Nikola Stenzel, Stefan Krumm, Jonathan Newman, Kevin S. Masters, Bart Verkuil, J. F. Brosschot, J. Rick Turner, Tomohiko Muratsubaki, Shin Fukudo, Siqin Ye, Anthony Remaud   +67 more
openaire   +1 more source

Incremental net benefit of whole genome sequencing for newborns and children with suspected genetic disorders: Systematic review and meta-analysis of cost-effectiveness evidence

Health Policy, 2022
Marco Tartaglia, Americo Cicchetti, Bruno Dallapiccola   +2 more
exaly  

Incremental Cost-Effectiveness Ratio

2008
openaire   +1 more source

Inference for the Cost-Effectiveness Acceptability Curve and Cost-Effectiveness Ratio

PharmacoEconomics (Auckland), 2000
A. O'Hagan, John W. Stevens, Jacques Montmartin   +2 more
semanticscholar   +1 more source

Incremental Net Monetary Benefit of Bariatric Surgery: Systematic Review and Meta-Analysis of Cost-Effectiveness Evidences

Obesity Surgery, 2021
Usa Chaikledkaew, Ammarin Thakkinstian, Montarat Thavorncharoensap   +2 more
exaly  

A Clinician's Guide to Correct Cost-Effectiveness Analysis: Think Incremental Not Average

Canadian Journal of Psychiatry, 2008
Carolyn S Dewa, Jeffrey S. Hoch
exaly  

On Parametric Confidence Intervals for the Cost‐Effectiveness Ratio

, 2001
J. Gardiner, M. Huebner, J. Jetton, C. Bradley   +3 more
semanticscholar   +1 more source